Research
Hormonal
GLP-1 receptor agonists are associated with gastrointestinal side effects (nausea, vomiting, diarrhea) and potentially increased risks of pancreatitis and thyroid cancer.
GLP-1 agonists commonly cause GI issues like nausea and diarrhea, especially when starting or increasing the dose. Serious but rare risks include pancreatitis and thyroid cancer. Monitor your health and report severe symptoms to your doctor.
StrongSupportsHIGH confidence
Typische unerwünschte Begleiterscheinungen sind gastrointestinale Nebenwirkungen wie Übelkeit, Erbrechen, Durchfall, Aufstoßen und gastroösophagealer Reflux. Zu den schwerwiegenderen Nebenwirkungen gehören Pankreatitis, allergische Reaktionen, Nierenfunktionsstörungen und möglicherweise ein erhöhtes Schilddrüsenkarzinomrisiko.
Why this rating
Well-documented in clinical trials and post-marketing surveillance.
Source
Glucagon-like-peptide-1-Rezeptoragonisten: eine neue pharmakologische Behandlungsoption für psychiatrische Erkrankungen?
Hubertus Himmerich · Der Nervenarzt · 2025
DOI 10.1007/s00115-025-01813-x
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (e.g., liraglutide, semaglutide, tirzepatide) significantly reduce body weight and improve glycemic control in patients with Type 2 Diabetes and Obesity.Strong
- GLP-1 receptor agonists show potential therapeutic benefits for psychiatric conditions, including depression, anxiety, binge-eating disorder, and substance use disorders, though evidence quality varies.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →